JP2024506530A - フェロトーシス制御性細胞死の阻害剤としてのインドール、６－および７－アザインドール誘導体の使用 - Google Patents

フェロトーシス制御性細胞死の阻害剤としてのインドール、６－および７－アザインドール誘導体の使用 Download PDF

Info

Publication number
JP2024506530A
JP2024506530A JP2023545262A JP2023545262A JP2024506530A JP 2024506530 A JP2024506530 A JP 2024506530A JP 2023545262 A JP2023545262 A JP 2023545262A JP 2023545262 A JP2023545262 A JP 2023545262A JP 2024506530 A JP2024506530 A JP 2024506530A
Authority
JP
Japan
Prior art keywords
group
alkyl
aryl
heterocyclyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506530A5 (https=
Inventor
ステファヌ、バック
アルノー、コンテ
クレール、デルーズ
マリー、テレーズ、ディマンシュ、ボワトレル
ピーター、ゴクジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seabelife
Universite de Rennes 1
Sorbonne Universite
Original Assignee
Seabelife
Universite de Rennes 1
Sorbonne Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seabelife, Universite de Rennes 1, Sorbonne Universite filed Critical Seabelife
Publication of JP2024506530A publication Critical patent/JP2024506530A/ja
Publication of JP2024506530A5 publication Critical patent/JP2024506530A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023545262A 2021-01-25 2022-01-25 フェロトーシス制御性細胞死の阻害剤としてのインドール、６－および７－アザインドール誘導体の使用 Pending JP2024506530A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305085.9 2021-01-25
EP21305085 2021-01-25
PCT/EP2022/051650 WO2022157392A1 (en) 2021-01-25 2022-01-25 Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death

Publications (2)

Publication Number Publication Date
JP2024506530A true JP2024506530A (ja) 2024-02-14
JP2024506530A5 JP2024506530A5 (https=) 2025-01-31

Family

ID=74553738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545262A Pending JP2024506530A (ja) 2021-01-25 2022-01-25 フェロトーシス制御性細胞死の阻害剤としてのインドール、６－および７－アザインドール誘導体の使用

Country Status (6)

Country Link
US (1) US20240116923A1 (https=)
EP (1) EP4281070A1 (https=)
JP (1) JP2024506530A (https=)
CN (1) CN117529317A (https=)
CA (1) CA3205853A1 (https=)
WO (1) WO2022157392A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206255A1 (ja) * 2024-03-29 2025-10-02 富士フイルム株式会社 被験物質の評価方法および被験物質の評価キット

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250127084A (ko) 2022-12-02 2025-08-26 시비라이프 조절된 괴사 억제제와 n-아세틸시스테인의 상승작용적 조합
WO2025078659A1 (en) 2023-10-12 2025-04-17 Seabelife Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525490A (ja) * 2010-05-06 2013-06-20 メルク・シャープ・エンド・ドーム・コーポレイション Ｆａａｈのモジュレータとして有用なアザインドール誘導体
WO2017054216A1 (zh) * 2015-10-01 2017-04-06 史利利 电磁炉及线圈盘
WO2017064217A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
WO2020113028A1 (en) * 2018-11-27 2020-06-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064216A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) N1- and n7-substituted sibiriline derivatives and their use as inhibitor of cellular necroptosis
WO2019106434A1 (en) * 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
BR112021017831A2 (pt) * 2019-03-11 2021-11-30 Collaborative Medicinal Dev Llc Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525490A (ja) * 2010-05-06 2013-06-20 メルク・シャープ・エンド・ドーム・コーポレイション Ｆａａｈのモジュレータとして有用なアザインドール誘導体
WO2017054216A1 (zh) * 2015-10-01 2017-04-06 史利利 电磁炉及线圈盘
WO2017064217A1 (en) * 2015-10-13 2017-04-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
WO2020113028A1 (en) * 2018-11-27 2020-06-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE FEBS JOURNAL, vol. 284, JPN6026011464, 2017, pages 3050 - 3068, ISSN: 0005822521 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025206255A1 (ja) * 2024-03-29 2025-10-02 富士フイルム株式会社 被験物質の評価方法および被験物質の評価キット

Also Published As

Publication number Publication date
CN117529317A (zh) 2024-02-06
EP4281070A1 (en) 2023-11-29
US20240116923A1 (en) 2024-04-11
CA3205853A1 (en) 2022-07-28
WO2022157392A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP2024506530A (ja) フェロトーシス制御性細胞死の阻害剤としてのインドール、６－および７－アザインドール誘導体の使用
CN101827593B (zh) 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
CN101687883B (zh) 囊性纤维化跨膜传导调节因子的调节剂
AU2018278311B2 (en) IRE1 small molecule inhibitors
ES2282637T3 (es) 1-(aminoalquil-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6.
CN105859712B (zh) 作为nadph氧化酶抑制剂的吡唑并吡啶衍生物
CN103570723B (zh) 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
JP7142022B2 (ja) Ｍａｌｔ１の阻害剤およびそれらの使用
PT2344492E (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
WO2018205938A1 (zh) Parp抑制剂、其药物组合物、制备方法和应用
WO2010117787A2 (en) Inhibiting eph b-3 kinase
BR112018075736B1 (pt) Composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
KR20140077964A (ko) 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
WO2020244530A1 (zh) 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
WO2021143937A1 (zh) 吡咯类化合物、其制备方法和药物组合物与用途
AU2014252584A1 (en) Anti-angiogenesis compound, intermediate and use thereof
CN106146473B (zh) 一种抗血管新生化合物
CN113811324A (zh) 小分子局部黏着斑激酶(fak)抑制剂
CN107847486A (zh) 1‑甲基‑d‑色氨酸的盐和前药
TW201625610A (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
CN108558876B (zh) 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用
CN117122602B (zh) 化合物在制备治疗和/或预防脂肪肝病及相关疾病的药物中的用途
CN114390924A (zh) 用于蛋白质降解的化合物、组合物和方法
WO2024061172A1 (zh) 一种脯氨酰羟化酶抑制剂及其用途
JP7527039B2 (ja) Ｇｌｕｔ１欠損症症候群の治療に使用するためのイソキノリン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260416